Protara director receives 31,000 stock options

Protara Therapeutics director Cynthia Smith received a grant of stock options as equity compensation.

Rhea-AI Filing Summary

Protara Therapeutics director Cynthia Smith received a grant of stock options as equity compensation. She was awarded options covering 31,000 shares of common stock at an exercise price of $3.94 per share. These options vest in full on the first anniversary of the grant date, provided she continues to serve on the board, and will also fully vest upon a Change of Control.

Insider Trade Summary

Grant/Award: 31,000 shares

Grant/Award 1 txn

Insider Smith Cynthia

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	31,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 31,000 contracts (Direct)

Footnotes (1)

1. F1. 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.

Key Figures

Option grant size: 31,000 options Exercise price: $3.94 per share Options outstanding after grant: 31,000 options +2 more

5 metrics

Option grant size 31,000 options Annual Grant to director Cynthia Smith

Exercise price $3.94 per share Stock Option (Right to Buy) grant

Options outstanding after grant 31,000 options Total derivative securities following transaction

Vesting schedule 1-year cliff vesting Vests in full on first anniversary of grant

Expiration date June 14, 2036 Option term end date

Key Terms

Stock Option (Right to Buy), Annual Grant, Change of Control, exercise price

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Annual Grant financial

"The shares subject to the Annual Grant will vest in full"

Change of Control financial

"and will vest in full upon a Change of Control."

A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.

exercise price financial

"conversion_or_exercise_price: 3.9400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Protara Therapeutics (TARA) report for Cynthia Smith?

Protara Therapeutics reported that director Cynthia Smith received a grant of stock options covering 31,000 shares of common stock. The options are a form of equity compensation and were not purchased in the open market.

What is the exercise price of Cynthia Smith’s new stock options at Protara Therapeutics (TARA)?

Cynthia Smith’s new stock options have an exercise price of $3.94 per share. This means she can buy Protara Therapeutics common stock at $3.94 per share once the options vest and are exercised, subject to the grant’s terms.

How many Protara Therapeutics (TARA) shares are covered by Cynthia Smith’s option grant?

The option grant to Cynthia Smith covers 31,000 shares of Protara Therapeutics common stock. These options give her the right to buy that number of shares in the future at a fixed exercise price, once vested.

When do Cynthia Smith’s Protara Therapeutics (TARA) options vest?

Cynthia Smith’s options from the Annual Grant vest in full on the first anniversary of the grant date. Vesting is conditioned on her continuing to serve as a board member through that date, according to the grant’s terms.

What happens to Cynthia Smith’s Protara Therapeutics (TARA) options if there is a Change of Control?

If there is a Change of Control, Cynthia Smith’s Annual Grant options will vest in full immediately. This accelerated vesting provision allows all unvested options from this grant to become exercisable upon such a corporate transaction.

Did Cynthia Smith buy or sell Protara Therapeutics (TARA) shares in the market?

The reported transaction is a grant of stock options to Cynthia Smith, not a market trade. It reflects equity compensation awarded by Protara Therapeutics rather than an open-market purchase or sale of existing shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/16/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Cynthia

(Last) (First) (Middle)

C/O PROTARA THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, 3RD FLOOR

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protara Therapeutics, Inc. [ TARA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.94	06/15/2026		A		31,000		06/15/2027(1)	06/14/2036	Common Stock	31,000	$0	31,000	D

Explanation of Responses:

1. 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.

Remarks:

	/s/ Mary Grendell, Attorney-in-fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)